The role (if any) of chemotherapy in hepatocellular carcinoma

Affiliations

¹ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Weill Cornell Medical Colleage, New York, NT, USA. Electronic address: abou-alg@mskcc.org.

Comment

Imane El Dika et al. Lancet Gastroenterol Hepatol. 2017 Jun.

. 2017 Jun;2(6):387-389.

doi: 10.1016/S2468-1253(17)30104-8. Epub 2017 Apr 6.

¹ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Weill Cornell Medical Colleage, New York, NT, USA. Electronic address: abou-alg@mskcc.org.

No abstract available

Comment on

S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M, Okusaka T. Kudo M, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):407-417. doi: 10.1016/S2468-1253(17)30072-9. Epub 2017 Apr 6. Lancet Gastroenterol Hepatol. 2017. PMID: 28497756 Clinical Trial.